These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 11747327

  • 1. A phase II trial of marimastat in advanced pancreatic cancer.
    Evans JD, Stark A, Johnson CD, Daniel F, Carmichael J, Buckels J, Imrie CW, Brown P, Neoptolemos JP.
    Br J Cancer; 2001 Dec 14; 85(12):1865-70. PubMed ID: 11747327
    [Abstract] [Full Text] [Related]

  • 2. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies.
    Nemunaitis J, Poole C, Primrose J, Rosemurgy A, Malfetano J, Brown P, Berrington A, Cornish A, Lynch K, Rasmussen H, Kerr D, Cox D, Millar A.
    Clin Cancer Res; 1998 May 14; 4(5):1101-9. PubMed ID: 9607566
    [Abstract] [Full Text] [Related]

  • 3. Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen.
    Primrose JN, Bleiberg H, Daniel F, Van Belle S, Mansi JL, Seymour M, Johnson PW, Neoptolemos JP, Baillet M, Barker K, Berrington A, Brown PD, Millar AW, Lynch KP.
    Br J Cancer; 1999 Feb 14; 79(3-4):509-14. PubMed ID: 10027321
    [Abstract] [Full Text] [Related]

  • 4. Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.
    Levitt NC, Eskens FA, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ, Choi L, Foekens JA, Wilner S, Wood JM, Nakajima M, Talbot DC, Steward WP, Harris AL, Verweij J.
    Clin Cancer Res; 2001 Jul 14; 7(7):1912-22. PubMed ID: 11448904
    [Abstract] [Full Text] [Related]

  • 5. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196.
    Sparano JA, Bernardo P, Stephenson P, Gradishar WJ, Ingle JN, Zucker S, Davidson NE.
    J Clin Oncol; 2004 Dec 01; 22(23):4683-90. PubMed ID: 15570070
    [Abstract] [Full Text] [Related]

  • 6. Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, Marimastat in patients with inoperable colorectal hepatic metastases: significant survival advantage in patients with musculoskeletal side-effects.
    King J, Zhao J, Clingan P, Morris D.
    Anticancer Res; 2003 Dec 01; 23(1B):639-45. PubMed ID: 12680160
    [Abstract] [Full Text] [Related]

  • 7. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
    Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA.
    Br J Cancer; 2002 Jul 15; 87(2):161-7. PubMed ID: 12107836
    [Abstract] [Full Text] [Related]

  • 8. Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
    Rosenbaum E, Zahurak M, Sinibaldi V, Carducci MA, Pili R, Laufer M, DeWeese TL, Eisenberger MA.
    Clin Cancer Res; 2005 Jun 15; 11(12):4437-43. PubMed ID: 15958628
    [Abstract] [Full Text] [Related]

  • 9. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
    Hayashi K, Imaizumi T, Uchida K, Kuramochi H, Takasaki K.
    Oncol Rep; 2002 Jun 15; 9(6):1355-61. PubMed ID: 12375048
    [Abstract] [Full Text] [Related]

  • 10. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial.
    Friess H, Beger HG, Kunz J, Funk N, Schilling M, Büchler MW.
    Anticancer Res; 1996 Jun 15; 16(2):915-20. PubMed ID: 8687151
    [Abstract] [Full Text] [Related]

  • 11. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
    Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP.
    Ann Surg Oncol; 2004 Jul 15; 11(7):644-9. PubMed ID: 15197014
    [Abstract] [Full Text] [Related]

  • 12. Trofosfamide in patients with pancreatic cancer.
    Schmidt-Sandte W, Dageförde J, Klapdor R, Wagner T, Wiedemann GJ.
    Anticancer Res; 1999 Jul 15; 19(4A):2485-7. PubMed ID: 10470179
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid.
    Eatock M, Cassidy J, Johnson J, Morrison R, Devlin M, Blackey R, Owen S, Choi L, Twelves C.
    Cancer Chemother Pharmacol; 2005 Jan 15; 55(1):39-46. PubMed ID: 15368080
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer.
    Ishii H, Okada S, Sato T, Wakasugi H, Saisho H, Furuse J, Ishikawa O, Matsuno S, Yokoyama S.
    Hepatogastroenterology; 1997 Jan 15; 44(13):279-83. PubMed ID: 9058159
    [Abstract] [Full Text] [Related]

  • 20. Early clinical experience using high intensity focused ultrasound for palliation of inoperable pancreatic cancer.
    Xiong LL, Hwang JH, Huang XB, Yao SS, He CJ, Ge XH, Ge HY, Wang XF.
    JOP; 2009 Mar 09; 10(2):123-9. PubMed ID: 19287104
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.